…
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. It operates through two segments: Private-Label Contract Manufacturing, and Patent and Trademark Licensing. The company offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, the company sells beta-alanine ingredient under the CarnoSyn, TriBsynm, and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Natural Alternatives International, Inc. manufactures and supplies dietary supplements and nutritional ingredients and provides contract manufacturing along with related R&D and packaging services for consumer health brands. Long-term growth drivers include secular demand for health and wellness products, continued outsourcing of production by brand owners, and potential international expansion, which may benefit revenue diversification and operational scale; investors may find the company attractive for its manufacturing capabilities and service-oriented model.
Key risks include regulatory and quality-compliance exposure in the dietary-supplement sector, competitive pressures and pricing, and supply-chain and raw-material cost volatility that could affect production and profitability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -10.74M | -9.46M | 3.56M | 13.66M | 12.12M |
| Net income | -13.57M | -7.22M | 2.52M | 10.71M | 10.77M |
| Selling general administrative | 16.15M | 15.10M | 14.87M | 16.95M | 16.90M |
| Selling and marketing expenses | 0.40M | 0.30M | - | - | - |
| Gross profit | 9.29M | 6.87M | 18.16M | 30.51M | 30.44M |
| Reconciled depreciation | 4.56M | 4.65M | 4.25M | 4.17M | 4.34M |
| Ebit | -7.26M | -9.10M | 4.66M | 13.68M | 9.33M |
| Ebitda | -2.70M | -4.46M | 8.91M | 17.79M | 13.67M |
| Depreciation and amortization | 4.56M | 4.65M | 4.25M | 4.11M | 4.34M |
| Operating income | -8.66M | -8.53M | 4.71M | 13.68M | 9.33M |
| Other operating expenses | 138.52M | 122.33M | 149.30M | 157.29M | 164.85M |
| Interest expense | 0.92M | 0.36M | 0.45M | 0.08M | 0.12M |
| Tax provision | 2.83M | -2.25M | 1.03M | 2.95M | 1.36M |
| Interest income | 0.17M | 0.18M | 0.03M | 0.00M | 0.00M |
| Net interest income | -0.75M | -0.18M | -0.42M | -0.08M | -0.12M |
| Income tax expense | 2.83M | -2.25M | 1.03M | 2.95M | 1.36M |
| Total revenue | 129.86M | 113.80M | 154.01M | 170.97M | 178.52M |
| Total operating expenses | 17.95M | 15.40M | 13.45M | 16.83M | 16.77M |
| Cost of revenue | 120.57M | 106.93M | 135.86M | 140.46M | 148.08M |
| Total other income expense net | -2.08M | -0.93M | -0.74M | -0.02M | 2.79M |
| Net income from continuing ops | -13.57M | -7.22M | 2.52M | 10.71M | 10.77M |
| Net income applicable to common shares | - | - | 2.52M | 10.71M | 10.77M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 151.94M | 162.34M | 134.15M | 146.00M | 120.28M |
| Other current assets | 7.16M | 8.49M | 6.00M | 1.80M | 3.26M |
| Total liab | 83.51M | 79.75M | 45.38M | 57.48M | 40.20M |
| Total stockholder equity | 68.43M | 82.59M | 88.77M | 88.52M | 80.08M |
| Other current liab | 7.25M | 5.03M | 5.03M | 6.63M | 0.81M |
| Common stock | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M |
| Capital stock | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M |
| Retained earnings | 59.39M | 72.97M | 80.18M | 77.66M | 66.95M |
| Other liab | - | - | 1.33M | 2.68M | 1.65M |
| Other assets | - | - | 2.40M | 2.98M | 1.78M |
| Cash | 12.32M | 11.98M | 13.60M | 21.83M | 32.13M |
| Total current liabilities | 28.80M | 23.46M | 15.88M | 23.26M | 23.72M |
| Current deferred revenue | 1.36M | 0.30M | 0.32M | 0.14M | 1.72M |
| Net debt | 46.70M | 48.31M | 17.33M | 10.01M | -15.65M |
| Short term debt | 4.43M | 4.89M | 2.76M | 0.30M | 9.29M |
| Short long term debt | 2.21M | 3.70M | 0.31M | 0.30M | - |
| Short long term debt total | 59.03M | 60.29M | 30.93M | 31.84M | 16.48M |
| Other stockholder equity | 10.36M | 9.56M | 8.58M | 9.07M | 13.61M |
| Property plant equipment | - | - | 74.21M | 66.27M | 38.15M |
| Total current assets | 59.28M | 61.61M | 57.01M | 76.75M | 80.35M |
| Net tangible assets | - | - | 88.77M | 88.52M | 80.08M |
| Net receivables | 14.92M | 16.89M | 7.33M | 17.49M | 17.95M |
| Long term debt | 8.63M | 8.93M | 9.21M | 9.49M | - |
| Inventory | 24.87M | 24.25M | 29.69M | 32.48M | 27.01M |
| Accounts payable | 15.35M | 12.74M | 7.78M | 16.18M | 11.89M |
| Accumulated other comprehensive income | -1.42M | -0.02M | -0.08M | 1.70M | -0.56M |
| Common stock total equity | - | - | - | - | 0.09M |
| Non currrent assets other | 0.72M | 4.91M | 2.58M | 2.98M | 1.57M |
| Non current assets total | 92.66M | 100.73M | 77.14M | 69.26M | 39.93M |
| Capital lease obligations | 48.20M | 47.66M | 21.41M | 22.05M | 16.48M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -3.61M | -3.02M | -13.47M | -26.46M | -5.04M |
| Change to liabilities | - | - | -8.61M | 3.06M | 1.91M |
| Total cashflows from investing activities | -3.61M | -3.02M | -13.47M | -26.46M | -5.04M |
| Net borrowings | -1.80M | 3.11M | -0.28M | 9.79M | -10.00M |
| Total cash from financing activities | -1.97M | 2.89M | -1.78M | 4.29M | -14.11M |
| Change to operating activities | - | - | -7.06M | -6.12M | -0.25M |
| Net income | -13.57M | -7.22M | 2.52M | 10.71M | 10.77M |
| Change in cash | 0.34M | -1.62M | -8.23M | -10.30M | 1.66M |
| Begin period cash flow | 11.98M | 13.60M | 21.83M | 32.13M | 30.48M |
| End period cash flow | 12.32M | 11.98M | 13.60M | 21.83M | 32.13M |
| Total cash from operating activities | 5.93M | -1.50M | 7.02M | 11.87M | 20.81M |
| Issuance of capital stock | - | - | - | - | 0.04M |
| Depreciation | 4.56M | 4.65M | 4.25M | 4.17M | 4.34M |
| Dividends paid | - | - | - | - | 10.00M |
| Change to inventory | -0.62M | 5.45M | 2.78M | -5.47M | 0.97M |
| Change to account receivables | 2.25M | -9.87M | 11.82M | 0.64M | -0.81M |
| Sale purchase of stock | -0.18M | -0.22M | -1.50M | -5.50M | -4.15M |
| Other cashflows from financing activities | - | -3.02M | -13.47M | 10.00M | 10.00M |
| Change to netincome | - | - | 1.48M | 4.42M | 4.62M |
| Capital expenditures | 3.61M | 3.02M | 13.52M | 26.49M | 5.11M |
| Change in working capital | 1.57M | -3.35M | -1.23M | -7.43M | 1.08M |
| Stock based compensation | 0.98M | 1.20M | 1.01M | 0.97M | 1.43M |
| Other non cash items | 8.78M | 6.13M | 1.44M | 2.70M | 3.40M |
| Free cash flow | 2.32M | -4.51M | -6.50M | -14.62M | 15.70M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NAII Natural Alternatives International |
0.02 1.69% |
0.97 | - | 13.61 | 0.09 | 0.20 | 0.48 | 74.97 |
| NSRGF Nestle SA |
0.32 0.32% |
102.04 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
0.89 0.86% |
104.47 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| DANOY Danone PK |
0.19 1.24% |
15.46 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
| GPDNF Danone S.A |
2.93 3.90% |
78.15 | 20.30 | 14.75 | 1.65 | 2.24 | 1.76 | 10.92 |
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. It operates through two segments: Private-Label Contract Manufacturing, and Patent and Trademark Licensing. The company offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, the company sells beta-alanine ingredient under the CarnoSyn, TriBsynm, and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark A. LeDoux J.D. | Chairman & CEO | 1954 |
| Mr. Kenneth E. Wolf | Pres, COO & Sec. | 1961 |
| Mr. Michael E. Fortin | Chief Financial Officer | 1977 |
| Mr. Eugene M. Quast | VP of Global Sales | 1959 |
| Mr. Mark A. LeDoux J.D. | Chairman of the Board & CEO | 1954 |
| Mr. Kenneth E. Wolf | President, COO & Secretary | 1961 |
| Mr. Shane Conti | Vice President of Global Sales | NA |
| Mr. Kenneth E. Wolf CPA | President, COO, Secretary, Principal Financial & Principal Accounting Officer | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.